Latest Healthcare News

Global Health Limited boosted customer receipts by 25% in the March quarter while slashing operating cash burn by 50%, setting the stage for positive cashflow from July 2026 driven by AI-enhanced efficiencies and expanding SaaS integrations.

BCAL Diagnostics has expanded its Avantect cancer blood tests nationally through major pathology networks, generating $88,000 in Q3 revenue from 91 tests. The company also submitted an initial Medicare reimbursement application for pancreatic cancer detection and is preparing to launch an enhanced BREASTESTplus 2.0 test in early 2027.

EBOS Group has trimmed its FY26 underlying EBITDA forecast by up to AUD 15 million due to surging fuel and logistics expenses, while maintaining its commitment to healthcare supply continuity.

Firebrick Pharma secured regulatory approval for Nasodine Nasal Spray in Indonesia and launched Nasodine Throat Spray in Singapore and Fiji, while raising $1.5 million to fuel growth. The company aims to quadruple its product and market footprint within three years.

Compumedics maintains robust sales momentum but faces FY26 revenue timing challenges due to MEG installation delays and a cautious Somfit D rollout. The company expects solid year-on-year growth and positions for improved execution in FY27.

Vitura Health’s telehealth arm, Doctors on Demand, has hit a major milestone of over 1 million consultations since FY2024, while delivering sustained EBITDA profitability and a 54% revenue increase over two years to $21.6 million in FY2026 Q1-Q3.

Australian Clinical Labs has been hit with a class action lawsuit linked to a 2022 cyberattack on Medlab Pathology, alleging breaches of consumer law and duty of care. The company denies the claims and plans a vigorous defence.

Ramsay Health Care has announced a fully franked distribution of AUD 3.3608 per security on its perpetual preference shares, subject to board approval by late August. The payment reflects a total annualised rate of 6.7%, linked to the 180-day BBSW plus a margin.

Lumos Diagnostics has secured a key FDA 510(k) clearance with CLIA waiver for its FebriDx rapid test, unlocking a US$1 billion-plus market opportunity and triggering milestone payments exceeding US$6 million. The company reported a 37% revenue jump in Q3 FY26, supported by a A$20 million placement and ongoing clinical and development projects.

4DMedical lands a contract with pharma giant GSK, gains UKCA certification for its CT:VQ™ lung imaging technology, and joins the S&P/ASX 200, marking a significant step in its global expansion.

Emyria has unveiled the Empax Global Partnership Program, a high-margin clinical delivery platform targeting international drug sponsors amid growing demand for psychedelic-assisted mental health treatments.

Orthocell’s Q1 FY26 revenue hits $3.2 million, buoyed by growing US sales of its Remplir nerve repair device and a robust $48 million cash position supporting global expansion.